Mitigating Cardiovascular Risk Through Effective Lipid Management - Episode 4

Residual Cardiovascular Risk

Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.

EP. 1: The Burden of ASCVD and Evidence-Based Guidelines
EP. 2: A Patient’s Post-MI Journey
EP. 3: Improving the Care Continuum
Now Viewing
EP. 4: Residual Cardiovascular Risk
EP. 5: Who is an Ideal Patient for Early Intensive Lipid Lowering?
EP. 6: Finding the Optimal Statin Dose
EP. 7: Therapy Beyond Statins in the Inpatient Setting
EP. 8: Using Adjunct Therapies in LDL Management
EP. 9: Ensuring Continuity of Care for the ASCVD Patient
EP. 10: Unmet Needs in Lipid Management
EP. 11: Defining “Optimal Care” for ASCVD Within Health Systems
EP. 12: What Does a Multidisciplinary Team Look Like?
EP. 13: The Future of LDL Management for Patients With High-Risk ASCVD
EP. 14: Enhancing Patient Care Through Guideline Adherence
EP. 15: Improving Access to PCSK9 Inhibitors in the Inpatient Setting
EP. 16: Appropriate ASCVD Treatment Outside of Closed Health Systems
EP. 17: Utilizing Quality Metrics in ASCVD
EP. 18: Improving Patient and Provider Engagement
EP. 19: Treatment Disparities in the Management of ASCVD